Hematology

Belantamab mafodotin-blmf is a first-in-class, anti-B-cell maturation antigen therapy indicated for adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies.

Session presenters at ASCP 2022 Annual Meeting discuss the benefits and disadvantages of apixaban versus warfarin for anticoagulation.

Phase 3 trial evaluated luspatercept-aamt and shows highly statistically significant and clinically meaningful improvement in red blood cell transfusion for those with myelodysplastic syndromes.

Phase 2 APPLY-PNH trial shows positive results superiority vs anti-C5 treatment in adult patients with PNH with residual anemia despite prior therapy.

Understanding the novel mechanisms of multiple myeloma can help to develop better next-generation therapies that overcome drug resistance.

These study findings may have implications for monitoring for the development of ICANS in patients receiving CAR T-cell therapies for cancer, according to the authors.

Panelists at the AMCP Nexus conference discuss the burden of undertreated and untreated chronic kidney disease.

A researcher suggests that understanding specific cell function in the tumor microenvironment can help create effective and individualized immunotherapy cancer treatments.

Omidubicel is a stem cell-based product that utilizes nicotinamide to inhibit differentiation and to increase the migration, bone marrow homing, and engraftment efficiency of hematopoietic progenitor cells.

Researchers identified a new immunotherapeutic target that may be effectively treated with CAR T-cell therapy in patients with pretreated multiple myeloma.

Relapses remain a challenge in treating patients with leukemia.

Biology and disease type may help determine which therapeutic options could work best for patients with Waldenstrom macroglobulinemia.

Study results show that the frequency of adverse events decreased after the patients transitioned from combination therapy to monotherapy.

Belantamab mafodotin plus lenalidomide and dexamethasone was found tolerable with no new safety signals and enhanced response rates in patients with multiple myeloma.

Ivosidenib plus azacitidine shows benefits in event-free survival, overall survival, and clinical responses compared with placebo in patients with IDH1-mutated acute myeloid leukemia.

The functional and physical well-being and other scores from the survey are more favorable for those who were treated with the therapy, investigators say.

IDH inhibitors show encouraging results in patients with myelodysplastic syndrome, but longer follow ups are needed in a larger patient population to confirm the results.

Expert discusses whether epigenetic programs regulate human T cell exhaustion and whether epigenetic-based strategies can be used to enhance T cell-based therapies.

CAR T therapies are potentially revolutionizing the treatment of acute lymphoblastic leukemia (ALL).

After 4 years, the 1-time cost of valoctocogene roxaparvovec appeared to be more cost-effective than the annual cost of emicizumab prophylaxis for hemophilia A, according to a new Draft Evidence Report.

Receiving benefits from the SNAP program does not alleviate the issue, according to the analysis.

Management of marginal zone lymphoma was impacted by the COVID-19 pandemic because some treatment options can reduce B-cell-produced antibodies.

The agency’s decision data for the investigational factor VIII therapy from Sanofi and Soba is set for February 28, 2023.

The biosimilar is expected to be launched as a prefilled syringe in early 2023.

A high proportion of myeloid cells may contribute to recurrence in those with long progression-free survival by promoting cancer growth and/or suppressing antitumor immunity.